Receipt of Targeted Therapy and Survival Outcomes in Patients With Metastatic Colorectal Cancer.

ABSTRACT:

Importance

Professional society guidelines recommend treating patients with metastatic colorectal cancer with targeted therapies, including epithelial growth factor receptor (EGFR) inhibitors and vascular endothelial growth factor (VEGF) inhibitors, depending on the presence or absence of certain mutations. Since most studies of first-line targeted therapies have been limited by sample size, there is a need for larger studies using data from routine clinical care.

Objectives

To identify factors associated with receipt of first-line targeted therapies among patients with metastatic colorectal cancer for whom RAS or BRAF mutation data in the tumor were available and investigate whether targeted therapy is associated with survival.

Design, setting, and participants

This

SUBMITTER: Koroukian SM 

PROVIDER: S-EPMC9857024 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature